![]() |
市場調查報告書
商品編碼
2088911
血栓除去裝置市場:按器械類型、手術類型、應用和最終用戶分類-2026-2032年全球市場預測Blood Clot Retrieval Devices Market by Device Type, Procedure Type, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,血栓除去裝置市場將成長至 60.6 億美元,複合年成長率為 14.80%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 23億美元 |
| 預計年份:2026年 | 26.4億美元 |
| 預測年份 2032 | 60.6億美元 |
| 複合年成長率 (%) | 14.80% |
血栓除去裝置,包括血栓摘取支架栓器、抽吸導管、球囊引導管和輔助通路系統,在治療大血管閉塞引起的急性缺血性腦中風的血管內取栓術中發揮核心作用。其臨床證據充分可靠。 2015年發表的隨機對照試驗,以及美國心臟協會/美國卒中協會和歐洲卒中組織隨後修訂的指南,均已確立機械取栓術為合格患者的標準治療方法。符合條件的患者通常為發病0-6小時,但對於影像學檢查結果仔細的患者,發病時間可延長至24小時。
這項需求源自於全球中風的沉重負擔。世界衛生組織(WHO)將卒中列為全球主要死因和致殘原因之一,《全球疾病負擔研究》報告顯示,每年新增卒中病例超過1200萬例。對於醫院、保險公司和醫療設備製造商而言,這個市場正日益呈現出以下特徵:更快的再灌注、更高的首過療效、更便捷地獲得綜合卒中中心服務以及循證介入神經放射學工作流程的整合。
血栓除去裝置領域的競爭格局正從單一器材間的競爭轉向系統層面的卒中診療。先進的影像技術、移動中風單元、遠端中風網路、直接血管造影方案以及能夠縮短「入院至腹股溝」和「入院至再灌注」時間的血管造影術模式,共同塑造了血栓切除器械的臨床應用。目前,最具競爭力的器械策略主要集中在手術效率、導航、血栓清除、吸力以及對複雜神經血管解剖結構的適應性等方面。
人工智慧 (AI)血栓除去裝置的實際應用。 AI 驅動的影像平台可用於在 CT血管攝影檢查中標記疑似大血管閉塞,在灌注影像中評估梗塞核心和缺血半暗帶,輔助 ASPECTS 評分,並通知中風團隊。由於臨床獲益具有高度時效性,這些工具均與基於指引的取栓方案一致。
北美地區仍然是機械取栓術應用率較高的地區,其中美國和加拿大主導。在這些國家,獲得認證的綜合卒中中心、完善的保險報銷體係以及強大的介入神經放射學能力推動了機械取栓術的應用。在歐洲,德國、法國、英國、義大利和西班牙成熟的卒中網路是一大優勢,但歐盟醫療設備法規 (MDR) 的合規性、醫療技術評估的要求以及區域間醫療資源取得的差異,都在影響著機械取栓術的商業化進程和醫院的採購決策。
由於新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國在卒中治療流程成熟度、診斷影像取得和介入治療訓練方面存在差異,東協地區的成長模式呈現出多樣性。海灣合作理事會(GCC)地區的特點是政府主導的醫院投資、積極開展醫療旅遊以及集中採購體系,這些因素推動了重點醫療中心採用先進的神經血管技術。歐盟透過統一的市場准入原則提供規模經濟效益,但醫療器材法規(MDR)要求將臨床證據、品管系統、上市後臨床追蹤和可追溯性作為決定醫療設備可近性的關鍵因素。
美國憑藉著高手術量、FDA已通過核准的技術、成熟完善的卒中中心網路以及嚴格執行基於指南的取栓手術流程,在全球取栓手術商業化方面處於領先地位。加拿大則受益於省級中風系統的協調以及已建立的三級轉診途徑。墨西哥和巴西正在擴大取栓手術的覆蓋範圍,但在保險報銷、基礎設施和區域醫療能力方面存在差異。在歐洲,英國、德國、法國、義大利和西班牙的臨床應用正在積極推進。德國尤其擁有強大的醫院和介入治療能力;法國和西班牙正在推廣規範化的卒中治療路徑;義大利正透過發展專科中心來平衡區域醫療資源的不均衡;英國則致力於加強超急性卒中服務和轉診流程。俄羅斯存在潛在需求,但面臨的挑戰包括採購流程的複雜性以及獲得先進介入神經放射學治療的機會不均等。
產業領導者應優先考慮能夠證明更快再灌注、更高再灌注成功率、更低併發症風險、減少新栓塞發生以及改善功能預後的臨床證據。器械產品組合應同時滿足血栓摘取支架和抽吸先行兩種策略,並充分考慮大血管閉塞、遠端和中間血管導航、血栓成分差異、血管壁安全性以及與球囊引導導管和中間導管的兼容性。
本執行摘要綜合整合了來自權威來源的二手研究和證據審查,包括世界衛生組織關於中風負擔的參考資料、全球疾病負擔出版刊物、美國心臟協會/美國卒中協會和歐洲卒中組織 (ESO) 指南、同行評審的血栓切除術試驗、監管資料庫、醫院認證框架以及公開的報銷和採購資訊來源。
血栓除去裝置處於臨床緊迫性、成熟治療方案和不斷發展的中風醫療體系能力三者交會點。機械取栓術正從一項特殊手術轉變為合格的嚴重閉塞性卒中循證治療的核心要素,其持續廣泛應用需要更快的診斷、更合理的患者分配、一致的手術執行以及公平地獲得具備取栓能力的醫療機構資源。
The Blood Clot Retrieval Devices Market is projected to grow by USD 6.06 billion at a CAGR of 14.80% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.30 billion |
| Estimated Year [2026] | USD 2.64 billion |
| Forecast Year [2032] | USD 6.06 billion |
| CAGR (%) | 14.80% |
Blood clot retrieval devices, including stent retrievers, aspiration catheters, balloon guide catheters, and adjunctive access systems, are central to endovascular thrombectomy for acute ischemic stroke caused by large vessel occlusion. The clinical foundation is strong: randomized trials published in 2015 and subsequent guideline updates from the American Heart Association/American Stroke Association and European Stroke Organisation established mechanical thrombectomy as standard care for eligible patients, with selection commonly extending from 0-6 hours and up to 24 hours in carefully imaged patients.
Demand is supported by the global stroke burden. The World Health Organization identifies stroke as one of the leading causes of death and disability worldwide, while Global Burden of Disease research reports more than 12 million new strokes annually. For hospitals, payers, and device manufacturers, the market is increasingly defined by faster reperfusion, improved first-pass effect, broader access to comprehensive stroke centers, and evidence-based integration of neurointerventional workflows.
The blood clot retrieval devices landscape is shifting from device-only competition toward system-level stroke care. Clinical adoption is being shaped by advanced imaging, mobile stroke units, telestroke networks, direct-to-angiosuite protocols, and transfer models that reduce door-to-groin and door-to-reperfusion times. The most competitive device strategies now address procedural efficiency, navigability, clot integration, aspiration force, and compatibility across complex neurovascular anatomy.
Regulatory and purchasing dynamics are also transforming the market. The U.S. FDA continues to emphasize safety and performance evidence for neurovascular devices, while the European Union Medical Device Regulation has raised documentation and clinical evaluation requirements. At the same time, health systems are prioritizing outcomes, length-of-stay reduction, and stroke network coverage, making real-world evidence, physician training, and post-market surveillance essential differentiators.
Artificial intelligence is becoming a practical growth catalyst for blood clot retrieval devices by improving the speed and consistency of stroke identification. AI-enabled imaging platforms are used to flag suspected large vessel occlusion on CT angiography, estimate infarct core and penumbra on perfusion imaging, support ASPECTS scoring, and notify stroke teams. These tools align with guideline-based thrombectomy pathways because clinical benefit is highly time-sensitive.
The cumulative impact is strongest when AI is embedded into workflow rather than used as a standalone tool. Automated alerts can shorten triage, support transfer decisions from primary stroke centers to thrombectomy-capable hospitals, and help prioritize neurointerventional teams. Industry leaders should still pair AI adoption with clinical validation, bias monitoring, cybersecurity controls, and integration into electronic health records and picture archiving systems.
North America remains a high-adoption region, led by the United States and Canada, where comprehensive stroke center certification, established reimbursement, and strong neurointerventional capacity support mechanical thrombectomy utilization. Europe benefits from mature stroke networks in Germany, France, the United Kingdom, Italy, and Spain, although EU MDR compliance, health technology assessment expectations, and uneven regional access influence commercialization timelines and hospital purchasing decisions.
Asia-Pacific is an expanding opportunity base, with Japan, South Korea, Australia, China, and India investing in stroke infrastructure, imaging capacity, tertiary care networks, and specialist training. Latin America, including Brazil and Mexico, is improving thrombectomy access but remains constrained by public-private care gaps, reimbursement variability, and concentration of neurointerventional services in major urban centers. The Middle East, especially GCC countries, is expanding advanced hospital networks and stroke-ready care pathways, while Africa shows long-term need driven by stroke burden, limited CT and angiography availability, delayed presentation, and a shortage of neurointerventional specialists.
ASEAN presents a heterogeneous growth profile, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines at different stages of stroke pathway maturity, imaging access, and interventional workforce development. The GCC is characterized by government-backed hospital investment, medical tourism ambitions, and centralized purchasing, supporting adoption of advanced neurovascular technologies in leading centers. The European Union offers scale through harmonized market access principles, but MDR requirements make clinical evidence, quality systems, post-market clinical follow-up, and traceability decisive for device availability.
BRICS markets combine large stroke populations with uneven access to thrombectomy-capable centers, creating opportunities for tiered device portfolios, training, and public hospital partnerships. G7 markets remain early adopters of next-generation aspiration and stent retriever platforms because of established reimbursement, specialist density, stroke center certification, and advanced imaging infrastructure. NATO countries increasingly emphasize medical supply resilience, cybersecurity, emergency preparedness, and cross-border health system coordination, which can influence procurement expectations for critical neurovascular devices.
The United States leads global commercialization through high procedure volumes, FDA-cleared technologies, mature comprehensive stroke center networks, and strong adoption of guideline-based thrombectomy workflows, while Canada benefits from coordinated provincial stroke systems and established tertiary care referral pathways. Mexico and Brazil are expanding thrombectomy access but face reimbursement, infrastructure, and regional capacity variation. In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong clinical adoption, with Germany notable for hospital and interventional capacity, France and Spain advancing organized stroke pathways, Italy balancing regional healthcare variation with specialist center development, and the United Kingdom strengthening hyperacute stroke services and transfer protocols. Russia presents demand potential but is affected by procurement complexity and uneven access to advanced neurointerventional care.
In Asia-Pacific, China and India offer substantial long-term demand because of large stroke populations, expanding tertiary care, and increasing investment in imaging and catheterization infrastructure, while Japan and South Korea are advanced markets with strong imaging availability, aging populations, and specialist adoption. Australia supports guideline-driven care across major metropolitan centers, although geography creates transfer and time-to-treatment challenges. Across all countries, the strongest opportunities align with faster diagnosis, trained interventional teams, reliable device availability, reimbursement clarity, and integrated stroke networks that connect emergency medical services, imaging, neurology, and neurointervention.
Industry leaders should prioritize clinical evidence that demonstrates faster reperfusion, high rates of successful recanalization, lower complication risk, reduced embolization to new territories, and improved functional outcomes. Device portfolios should address both stent retriever and aspiration-first strategies, with attention to large vessel occlusion, distal and medium vessel navigation, clot composition variability, vessel wall safety, and compatibility with balloon guide and intermediate catheters.
Commercial execution should focus on stroke network development, physician education, simulation-based training, and partnerships with imaging and AI workflow vendors. Companies should also build region-specific access strategies, strengthen post-market surveillance, prepare for EU MDR documentation demands, and support real-world evidence generation with hospitals. The most resilient players will combine device innovation with workflow integration, supply continuity, cybersecurity readiness, and outcome-based value communication.
This executive summary is based on triangulated secondary research and evidence review from authoritative sources, including WHO stroke burden references, Global Burden of Disease publications, AHA/ASA and European Stroke Organisation guidelines, peer-reviewed thrombectomy trials, regulatory databases, hospital certification frameworks, and publicly available reimbursement and procurement information.
The methodology combines clinical evidence mapping, regulatory assessment, regional healthcare infrastructure analysis, and market signal validation. Insights were screened for relevance to blood clot retrieval devices, acute ischemic stroke workflows, neurovascular intervention, AI-enabled triage, and geographic adoption patterns. Emphasis was placed on verified data, guideline-supported practice, and observable structural drivers rather than speculative market claims.
Blood clot retrieval devices are positioned at the intersection of clinical urgency, proven intervention, and expanding stroke system capability. Mechanical thrombectomy has moved from a specialized procedure to a core component of evidence-based care for eligible large vessel occlusion stroke, and continued adoption depends on faster diagnosis, better patient routing, consistent procedural performance, and equitable access to thrombectomy-capable centers.
The next phase of competition will be defined by integrated value: advanced device design, AI-supported workflow, strong training programs, regulatory readiness, and real-world outcomes. Organizations that align innovation with regional access needs, clinical evidence standards, and health system priorities will be best placed to support sustainable growth in the global thrombectomy market.